Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company developing precision therapies for neurodegenerative and inflammatory diseases, has raised $12 million in Series A financing to advance its lead drug candidate and expand its therapeutic pipeline. The financing was led by Double Point Ventures, with participation from new and existing investors. The company will use the proceeds to support development of LHP588, its lead program targeting a defined subset of Alzheimer’s disease patients, and to continue advancing its research efforts.

Founded in 2022, Lighthouse Pharmaceuticals is focused on developing small-molecule therapies designed to address major unmet medical needs. The company’s approach centers on precision medicine, using biological insights and patient-specific characteristics to identify populations that may benefit most from targeted treatments. Lighthouse is currently advancing LHP588, a next-generation gingipain inhibitor being evaluated for the treatment of P. gingivalis-positive mild to moderate Alzheimer’s disease.

The Series A investment represents a significant milestone for Lighthouse as it moves deeper into clinical development. The company said the financing will support its ongoing SPRING clinical trial, a Phase 2 study evaluating LHP588 in patients with Alzheimer’s disease associated with P. gingivalis infection. The trial is designed to evaluate whether targeting gingipains, toxic enzymes produced by P. gingivalis bacteria, can provide therapeutic benefits for a specific group of Alzheimer’s patients.

Double Point Ventures led the Series A round and joined Lighthouse’s efforts to advance its clinical pipeline. The venture firm focuses on investments in life sciences companies developing innovative therapies and technologies. As part of the financing, Campbell Murray, M.D., a partner at Double Point Ventures, joined Lighthouse’s Board of Directors, bringing experience in life sciences investing, company development, and clinical-stage strategy.

Lighthouse’s funding comes at a time when Alzheimer’s disease research is increasingly focused on identifying specific biological drivers that contribute to disease progression. While Alzheimer’s has traditionally been viewed as a complex neurological disorder with multiple contributing factors, researchers are increasingly exploring targeted approaches aimed at specific mechanisms and patient groups. Lighthouse’s LHP588 program reflects this shift toward precision therapeutic strategies.

The company’s lead program, LHP588, is based on the hypothesis that inhibiting gingipains may help address a potential biological pathway involved in Alzheimer’s disease. P. gingivalis, a bacterium associated with periodontal disease, has been studied for its possible connection to neurodegenerative processes. Lighthouse is investigating whether patients with evidence of P. gingivalis involvement could represent a subgroup that responds to targeted treatment.

In addition to the Series A financing, Lighthouse has received significant non-dilutive support for its Alzheimer’s research. The company’s SPRING clinical trial is supported by a $49.2 million grant from the National Institute on Aging, part of the National Institutes of Health. The grant supports the advancement of the Phase 2 study and highlights continued public-sector interest in innovative Alzheimer’s disease research.

Lighthouse has built its development strategy around combining clinical research, patient responder analysis, and biomarker-driven approaches. The company aims to improve the likelihood of therapeutic success by identifying patients most likely to benefit from its treatments rather than pursuing a broad, one-size-fits-all approach.

The company’s pipeline expansion efforts are also supported by the new financing. Beyond LHP588, Lighthouse is exploring additional opportunities in neurodegenerative and inflammatory diseases where precision therapeutics could address significant medical needs. The funding gives the company resources to continue evaluating new scientific opportunities while progressing its lead clinical program.

The investment follows earlier support from organizations including Portfolia and other investors identified as part of Lighthouse’s broader funding history. The company has raised capital through multiple financing activities as it advances its research and clinical programs.

Lighthouse Pharmaceuticals has also expanded its scientific and operational presence as it advances its Alzheimer’s program. The company relocated its headquarters to the Buck Institute for Research on Aging, a move aimed at supporting collaboration and research efforts focused on aging-related diseases.

With its $12 million Series A financing led by Double Point Ventures and support from additional investors, Lighthouse Pharmaceuticals plans to continue advancing LHP588 through clinical development and expanding its pipeline of precision therapies. The company’s goal is to develop targeted treatments that address specific disease mechanisms and provide new options for patients affected by neurodegenerative and inflammatory conditions.

Related Articles